Bellus Health Inc said Celtic
Therapeutics agreed to buy the rights to its drug candidate to
treat a potentially life-threatening condition for upfront
payments of $10 million, sending its shares up as much as 47
percent Thursday afternoon.
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.